Outlook and Strategic Focus after Institutional Placement
Open Briefing with CEO & MD Deborah Rathjen
Bionomics (ASX : BNO) is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system (CNS).
Current Market Cap: $232 million
In this Open Briefing , CEO & MD Deborah Rathjen discusses
- Outlook and strategic focus after raising capital and repositioning the register
- Sufficiently funded to execute licensing strategy and invest in development pipeline
- Update on development and partnering opportunities for BNC105 and BNC210
Download this document
